Collaboration to accelerate clinical translation
The Julius Wolff Institute of the Charité - Universitätsmedizin Berlin and the Wyss Institute for Biologically Inspired Engineering of Harvard University in the USA have signed a cooperation agreement to cooperate more closely in the future. The thematic focus of the collaborations is cell and tissue technology. Here, the scientists want to jointly develop novel biomaterials for regenerative therapies. The aim of the collaboration is to strengthen and accelerate the translation of research findings into clinical applications.
"The Charité is one of the world's leading institutions in clinical translation and basic medical research. The cooperation will increase the international reach of both institutes," said Don Ingber, founding director of the Wyss Institute. "I am very pleased that we have been able to expand the consortium of our many partnerships with the Charité. The joint research projects will drive the process of translating our material- and cell-based regenerative technologies into clinical trials". The Boston researchers are particularly interested in the proven clinical expertise that exists, for example, in the Centre for Musculoskeletal Surgery.
The cooperation agreement formalizes the two-year collaboration between Prof. Georg Duda, director of the Julius Wolff Institute and spokesperson of the Graduate School Berlin-Brandenburg School for Regenerative Therapies (BSRT) and David Mooney, bioengineer at the Harvard School of Engineering and Applied Sciences and faculty member of the Wyss Institute. Three years ago, David Mooney was one of the first professors to be appointed to the programme "Einstein Visiting Fellow" of the Einstein Stiftung Berlin an die Berlin-Brandenburg School for Regenerative Therapies. The aim of this programme is to integrate foreign top scientists into the Berlin research and science landscape on a long-term basis and thus further strengthen the international visibility of Berlin universities and research institutions.
The cooperation agreement resulting from this connection also includes the admission of Prof. Duda as a faculty member of the Wyss Institute at Harvard University and the opportunity to enable Berlin scientists to spend an uncomplicated research stay at the Wyss Institute in Boston.
"Through our cooperation, we can utilize the diverse capacities of the Wyss Institute in the fields of biotechnology," explains Prof. Duda. "Together, we will deliver new technologies and therapies to physicians and patients much faster and more effectively than if each partner were to act on its own."
Julius Wolff Institute
Phone: +49 30 450 559 048
Back to Overview